サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1641752

経鼻ドラッグデリバリーデバイスの世界市場：システム別、容器別、用途別 - 機会分析と産業予測（2024年～2033年）

Intranasal Drug Delivery Devices Market By System , By Container By Application : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
経鼻ドラッグデリバリーデバイスの世界市場：システム別、容器別、用途別 - 機会分析と産業予測（2024年～2033年）
出版日: 2024年11月01日
発行: Allied Market Research
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の経鼻ドラッグデリバリーデバイスの市場規模は、2023年に17億米ドルと評価され、2024年～2033年にCAGR 8.7%で成長し、2033年には38億米ドルに達すると予測されています。

Intranasal Drug Delivery Devices Market-IMG1

経鼻ドラッグデリバリーデバイスは、鼻腔から治療薬を投与するように設計された医療機器です。この投与経路は、消化管や肝臓での初回通過代謝をバイパスして、薬剤を直接全身循環に送り込んだり、中枢神経系を標的にしたりする非侵襲的かつ効率的な手段を提供します。経鼻デバイスには一般的に、鼻腔スプレー、ネブライザー、粉末ディスペンサーなどがあり、鼻粘膜からの薬物吸収を高めるように調整されています。

世界の経鼻ドラッグデリバリーデバイス市場の成長は、呼吸器疾患、アレルギー、片頭痛、またてんかんやオピオイドの過剰摂取のような迅速な薬物作用を必要とする病態の憂慮すべき有病率の増加が原動力となっています。公衆衛生研究機関であるInstitute for Health Metrics and Evaluationが発表した調査によると、慢性呼吸器疾患は2019年に4億5,460万件の有病率で400万人の死亡の原因となっており、死因の第3位となっています。また、患者の間で非侵襲的なドラッグデリバリー方法に対する需要が急増しており、慢性および急性の両方の症状に対する経鼻デバイスの採用を後押ししています。さらに、経鼻ドラッグデリバリーは、薬剤が血液脳関門を迂回できるため、中枢神経系をターゲットにするのに有効です。このため、アルツハイマー病やパーキンソン病などの神経疾患の治療研究が促進されています。さらに、在宅ヘルスケアやセルフメディケーションの動向の高まりが、経鼻デバイスを含む使いやすいドラッグデリバリーシステムの需要を促進しており、市場の成長を大きく促進しています。しかし、経鼻デバイスの頻繁な使用は、鼻粘膜に刺激、乾燥、その他の不快感を引き起こす可能性があるため、その採用が制限され、市場成長の妨げとなっています。さらに、安定性の問題や鼻粘膜からの透過性の低さから、すべての薬剤が経鼻デリバリーに適しているわけではなく、こうしたデバイスの応用範囲が制限されます。その一方で、定量点鼻薬や針を使わないデバイスなどの技術革新は、ドラッグデリバリーの精度と使いやすさを向上させています。投与量追跡用のセンサーと統合されたスマートデバイスも登場しており、患者の服薬アドヒアランスを向上させています。このような開発は、予測期間中の世界市場拡大に有益な機会を提供すると期待されます。

経鼻ドラッグデリバリーデバイス業界は、システム、容器、用途、地域に区分されます。システム別では、市場は定量投与システム、多回投与システム、単位投与システムに分別されます。容器別では、非加圧容器と加圧容器に二分されます。用途別では、慢性閉塞性肺疾患（COPD）、鼻炎、嚢胞性線維症、鼻づまり、喘息、その他に分けられます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで市場を分析しています。

主な調査結果

システム別では、2024年～2033年に多回投与システムセグメントが市場を独占すると予測されます。

容器別では、非加圧システム容器セグメントが予測期間中に最も高い成長を示すと予測されます。

用途別では、喘息セグメントが近い将来顕著なペースで成長すると予測されています。

地域別では、北米が2023年に経鼻ドラッグデリバリーデバイス市場で最大の市場シェアを占め、予測期間中も市場を独占すると予測されます。

本レポートで可能なレポートカスタマイズ（追加費用とタイムラインに関しましては販売担当へご連絡ください）

  • 顧客の関心に応じた企業プロファイルの追加
  • 過去の市場データ
  • 輸出入分析/データ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 経鼻ドラッグデリバリーデバイス市場：システム別

  • 市場概要
  • 定量投与
  • 多回投与システム
  • 単位投与システム

第5章 経鼻ドラッグデリバリーデバイス市場：容器別

  • 市場概要
  • 非加圧容器
  • 加圧容器

第6章 経鼻ドラッグデリバリーデバイス市場：用途別

  • 市場概要
  • 慢性閉塞性肺疾患
  • 鼻炎
  • 嚢胞性線維症
  • 鼻づまり
  • 喘息
  • その他

第7章 経鼻ドラッグデリバリーデバイス市場：地域別

  • 市場概要
  • 北米
    • 主な市場動向と機会
    • 米国の経鼻ドラッグデリバリーデバイス市場
    • カナダの経鼻ドラッグデリバリーデバイス市場
    • メキシコの経鼻ドラッグデリバリーデバイス市場
  • 欧州
    • 主要市場動向と機会
    • フランスの経鼻ドラッグデリバリーデバイス市場
    • ドイツの経鼻ドラッグデリバリーデバイス市場
    • イタリアの経鼻ドラッグデリバリーデバイス市場
    • スペインの経鼻ドラッグデリバリーデバイス市場
    • 英国の経鼻ドラッグデリバリーデバイス市場
    • その他欧州の経鼻ドラッグデリバリーデバイス市場
  • アジア太平洋
    • 主な市場動向と機会
    • 中国の経鼻ドラッグデリバリーデバイス市場
    • 日本の経鼻ドラッグデリバリーデバイス市場
    • インドの経鼻ドラッグデリバリーデバイス市場
    • 韓国の経鼻ドラッグデリバリーデバイス市場
    • オーストラリアの経鼻ドラッグデリバリーデバイス市場
    • その他アジア太平洋の経鼻ドラッグデリバリーデバイス市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの経鼻ドラッグデリバリーデバイス市場
    • 南アフリカの経鼻ドラッグデリバリーデバイス市場
    • サウジアラビアの経鼻ドラッグデリバリーデバイス市場
    • その他のラテンアメリカ・中東・アフリカの経鼻ドラッグデリバリーデバイス市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング：2023年

第9章 企業プロファイル

  • AptarGroup, Inc.
  • Teleflex Incorporated
  • Nemera
  • Becton, Dickinson And Company
  • OptiNose, Inc.
  • GlaxoSmithKline Plc.
  • AstraZeneca
  • Kurve Technology, Inc.
  • Johnson And Johnson
  • Merck And Co., Inc.
目次
Product Code: A324453

The intranasal drug delivery devices market was valued at $1.7 billion in 2023, and is projected to reach $3.8 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Intranasal Drug Delivery Devices Market - IMG1

Intranasal drug delivery devices are medical devices designed to administer therapeutic agents through the nasal cavity. This route of administration provides a non-invasive and efficient means to deliver drugs directly into the systemic circulation or target the central nervous system, bypassing the gastrointestinal tract and first-pass metabolism in the liver. Intranasal devices commonly include nasal sprays, nebulizers, and powder dispensers, tailored to enhance drug absorption through the nasal mucosa.

The growth of the global intranasal drug delivery devices market is driven by alarming increase in prevalence of respiratory diseases, allergies, migraines as well as conditions requiring rapid drug action, such as epilepsy and opioid overdose. According to a study published by the Institute for Health Metrics and Evaluation-a public health research institute-chronic respiratory diseases were responsible for 4.0 million deaths with a prevalence of 454.6 million cases in 2019, ranking as the third leading cause of death. In addition, surge in demand for non-invasive drug delivery methods among patients is boosting the adoption of intranasal devices for both chronic and acute conditions. Moreover, intranasal drug delivery is effective in targeting the central nervous system, as it allows drugs to bypass the blood-brain barrier. This is fostering research into treatments for neurological disorders, such as Alzheimer's and Parkinson's disease. Furthermore, rise of home healthcare and self-medication trends is driving the demand for easy-to-use drug delivery systems, including intranasal devices, which significantly fosters the market growth. However, frequent use of intranasal devices may cause irritation, dryness, or other discomfort in the nasal mucosa, which limits their adoption, thereby hampering the market growth. In addition, not all drugs are suitable for intranasal delivery due to stability issues or low permeability through the nasal mucosa, which restricts the range of applications for these devices. On the contrary, innovations such as metered-dose nasal sprays and needle-free devices improve drug delivery precision and user-friendliness. Smart devices integrated with sensors for dose tracking are also emerging, enhancing patient adherence. Such developments are expected to offer remunerative opportunities for the expansion of the global market during the forecast.

The intranasal drug delivery devices industry is segmented into system, container, application, and region. By system, the market is segregated into metered dose, multi-dose systems, and unit-dose systems. On the basis of containers, it is bifurcated into non-pressurized containers and pressurized containers. Depending on application, it is divided into chronic obstructive pulmonary disease (COPD) , rhinitis, cystic fibrosis, nasal congestion, asthma, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By system, the multi-dose systems segment is expected to dominate the market from 2024 to 2033.

On the basis of container, the non-pressurized system containers segment is anticipated to exhibit the highest growth during the forecast period.

Depending on application, the asthma segment is projected to grow at a notable pace in the near future.

Region wise, North America held the largest market share in the intranasal drug delivery devices market in 2023, and is expected to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global intranasal drug delivery devices market include AptarGroup, Inc., Teleflex Incorporated, Nemera, Becton, Dickinson and Company, OptiNose, Inc., GlaxoSmithKline Plc., AstraZeneca, Kurve Technology, Inc., Johnson & Johnson, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Historic market data
  • Import Export Analysis/Data

Key Market Segments

By System

  • Metered Dose
  • Multi-Dose Systems
  • Unit-Dose Systems

By Container

  • Non-Pressurized Containers
  • Pressurized Containers

By Application

  • Chronic Obstructive Pulmonary Disease
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • AptarGroup, Inc.
    • Teleflex Incorporated
    • nemera
    • Becton, Dickinson and Company
    • OptiNose, Inc.
    • GlaxoSmithKline plc.
    • AstraZeneca
    • Kurve Technology, Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY SYSTEM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By System
  • 4.2. Metered Dose
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Multi-Dose Systems
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Unit-Dose Systems
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY CONTAINER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Container
  • 5.2. Non-Pressurized Containers
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Pressurized Containers
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY APPLICATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Application
  • 6.2. Chronic Obstructive Pulmonary Disease
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Rhinitis
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Cystic Fibrosis
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Nasal Congestion
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country
  • 6.6. Others
    • 6.6.1. Key Market Trends, Growth Factors and Opportunities
    • 6.6.2. Market Size and Forecast, By Region
    • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By System
    • 7.2.3. Market Size and Forecast, By Container
    • 7.2.4. Market Size and Forecast, By Application
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Intranasal Drug Delivery Devices Market
      • 7.2.6.1. Market Size and Forecast, By System
      • 7.2.6.2. Market Size and Forecast, By Container
      • 7.2.6.3. Market Size and Forecast, By Application
    • 7.2.7. Canada Intranasal Drug Delivery Devices Market
      • 7.2.7.1. Market Size and Forecast, By System
      • 7.2.7.2. Market Size and Forecast, By Container
      • 7.2.7.3. Market Size and Forecast, By Application
    • 7.2.8. Mexico Intranasal Drug Delivery Devices Market
      • 7.2.8.1. Market Size and Forecast, By System
      • 7.2.8.2. Market Size and Forecast, By Container
      • 7.2.8.3. Market Size and Forecast, By Application
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By System
    • 7.3.3. Market Size and Forecast, By Container
    • 7.3.4. Market Size and Forecast, By Application
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Intranasal Drug Delivery Devices Market
      • 7.3.6.1. Market Size and Forecast, By System
      • 7.3.6.2. Market Size and Forecast, By Container
      • 7.3.6.3. Market Size and Forecast, By Application
    • 7.3.7. Germany Intranasal Drug Delivery Devices Market
      • 7.3.7.1. Market Size and Forecast, By System
      • 7.3.7.2. Market Size and Forecast, By Container
      • 7.3.7.3. Market Size and Forecast, By Application
    • 7.3.8. Italy Intranasal Drug Delivery Devices Market
      • 7.3.8.1. Market Size and Forecast, By System
      • 7.3.8.2. Market Size and Forecast, By Container
      • 7.3.8.3. Market Size and Forecast, By Application
    • 7.3.9. Spain Intranasal Drug Delivery Devices Market
      • 7.3.9.1. Market Size and Forecast, By System
      • 7.3.9.2. Market Size and Forecast, By Container
      • 7.3.9.3. Market Size and Forecast, By Application
    • 7.3.10. UK Intranasal Drug Delivery Devices Market
      • 7.3.10.1. Market Size and Forecast, By System
      • 7.3.10.2. Market Size and Forecast, By Container
      • 7.3.10.3. Market Size and Forecast, By Application
    • 7.3.11. Rest Of Europe Intranasal Drug Delivery Devices Market
      • 7.3.11.1. Market Size and Forecast, By System
      • 7.3.11.2. Market Size and Forecast, By Container
      • 7.3.11.3. Market Size and Forecast, By Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By System
    • 7.4.3. Market Size and Forecast, By Container
    • 7.4.4. Market Size and Forecast, By Application
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Intranasal Drug Delivery Devices Market
      • 7.4.6.1. Market Size and Forecast, By System
      • 7.4.6.2. Market Size and Forecast, By Container
      • 7.4.6.3. Market Size and Forecast, By Application
    • 7.4.7. Japan Intranasal Drug Delivery Devices Market
      • 7.4.7.1. Market Size and Forecast, By System
      • 7.4.7.2. Market Size and Forecast, By Container
      • 7.4.7.3. Market Size and Forecast, By Application
    • 7.4.8. India Intranasal Drug Delivery Devices Market
      • 7.4.8.1. Market Size and Forecast, By System
      • 7.4.8.2. Market Size and Forecast, By Container
      • 7.4.8.3. Market Size and Forecast, By Application
    • 7.4.9. South Korea Intranasal Drug Delivery Devices Market
      • 7.4.9.1. Market Size and Forecast, By System
      • 7.4.9.2. Market Size and Forecast, By Container
      • 7.4.9.3. Market Size and Forecast, By Application
    • 7.4.10. Australia Intranasal Drug Delivery Devices Market
      • 7.4.10.1. Market Size and Forecast, By System
      • 7.4.10.2. Market Size and Forecast, By Container
      • 7.4.10.3. Market Size and Forecast, By Application
    • 7.4.11. Rest of Asia-Pacific Intranasal Drug Delivery Devices Market
      • 7.4.11.1. Market Size and Forecast, By System
      • 7.4.11.2. Market Size and Forecast, By Container
      • 7.4.11.3. Market Size and Forecast, By Application
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By System
    • 7.5.3. Market Size and Forecast, By Container
    • 7.5.4. Market Size and Forecast, By Application
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Intranasal Drug Delivery Devices Market
      • 7.5.6.1. Market Size and Forecast, By System
      • 7.5.6.2. Market Size and Forecast, By Container
      • 7.5.6.3. Market Size and Forecast, By Application
    • 7.5.7. South Africa Intranasal Drug Delivery Devices Market
      • 7.5.7.1. Market Size and Forecast, By System
      • 7.5.7.2. Market Size and Forecast, By Container
      • 7.5.7.3. Market Size and Forecast, By Application
    • 7.5.8. Saudi Arabia Intranasal Drug Delivery Devices Market
      • 7.5.8.1. Market Size and Forecast, By System
      • 7.5.8.2. Market Size and Forecast, By Container
      • 7.5.8.3. Market Size and Forecast, By Application
    • 7.5.9. Rest of LAMEA Intranasal Drug Delivery Devices Market
      • 7.5.9.1. Market Size and Forecast, By System
      • 7.5.9.2. Market Size and Forecast, By Container
      • 7.5.9.3. Market Size and Forecast, By Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping Of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. AptarGroup, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Teleflex Incorporated
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Nemera
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Becton, Dickinson And Company
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. OptiNose, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. GlaxoSmithKline Plc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. AstraZeneca
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Kurve Technology, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Johnson And Johnson
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Merck And Co., Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments